State Street Corp Grows Holdings in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

State Street Corp increased its holdings in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 1.1% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,969,963 shares of the company’s stock after purchasing an additional 21,986 shares during the period. State Street Corp’s holdings in Olema Pharmaceuticals were worth $23,521,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of OLMA. Bank of New York Mellon Corp grew its holdings in shares of Olema Pharmaceuticals by 72.1% during the second quarter. Bank of New York Mellon Corp now owns 139,923 shares of the company’s stock worth $1,514,000 after buying an additional 58,622 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Olema Pharmaceuticals by 43.5% in the 2nd quarter. Rhumbline Advisers now owns 59,261 shares of the company’s stock valued at $641,000 after purchasing an additional 17,953 shares during the last quarter. Victory Capital Management Inc. increased its holdings in shares of Olema Pharmaceuticals by 26.9% in the second quarter. Victory Capital Management Inc. now owns 774,792 shares of the company’s stock valued at $8,383,000 after purchasing an additional 164,143 shares during the period. Candriam S.C.A. increased its holdings in shares of Olema Pharmaceuticals by 199.9% in the second quarter. Candriam S.C.A. now owns 1,058,673 shares of the company’s stock valued at $11,454,000 after purchasing an additional 705,655 shares during the period. Finally, ClariVest Asset Management LLC raised its stake in shares of Olema Pharmaceuticals by 3.1% during the second quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock worth $683,000 after purchasing an additional 1,881 shares during the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research report on Wednesday, December 11th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $27.00.

Olema Pharmaceuticals Trading Up 5.4 %

Shares of OLMA stock opened at $6.10 on Monday. Olema Pharmaceuticals, Inc. has a 12-month low of $5.56 and a 12-month high of $16.77. The company has a market cap of $349.52 million, a price-to-earnings ratio of -2.79 and a beta of 1.92. The stock has a 50 day simple moving average of $10.17 and a 200-day simple moving average of $11.71.

Insider Buying and Selling at Olema Pharmaceuticals

In other news, Director G. Walmsley Graham sold 700,761 shares of Olema Pharmaceuticals stock in a transaction that occurred on Tuesday, December 17th. The shares were sold at an average price of $6.75, for a total transaction of $4,730,136.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David C. Myles sold 12,452 shares of the company’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $9.38, for a total value of $116,799.76. Following the completion of the sale, the insider now owns 611,947 shares in the company, valued at approximately $5,740,062.86. This represents a 1.99 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 773,797 shares of company stock valued at $5,414,609. 19.40% of the stock is owned by company insiders.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.